Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Inc.

Morgan Stanley analyst Sean Laaman assigned a Hold rating to Neurocrine today and set a price target of $193.00. According to TipRanks, Laaman is a...

Morgan Stanley Issues a Hold Rating on Neurocrine (NBIX)

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Neurocrine, with a price target of $199.00. Ahm...

Bank of America Securities Reaffirms Their Buy Rating on Neurocrine (NBIX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Neurocrine (NBIX)...

Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)

In a report released today, from Jefferies maintained a Buy rating on Neurocrine, with a price target of $200.00. In a report released today, UBS a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NBIX	$182.83	+3.64%	1.33M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NBIX	$182.83	+3.6%	1.33M
3
4
5
6

NBIX

NBIX

Get Neurocrine Biosciences Inc. Data in Excel

Get Neurocrine Biosciences Inc. Data in Excel